Press Releases

Visionary, up to $2 billion multi-year alliance to focus on development of new gene therapy and gene editing technologies and create a therapeutic platform for a broad range of diseases Biogen to team up with renowned gene therapy...

Chugai Pharmaceutical Co Ltd. announced that it obtained a supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 13, 2016, for “CellCept®. Capsules 250” and “CellCept® Powder for Oral Suspension 31.8%”...

Chugai Pharmaceutical Co Ltd announced that its co-sponsorship of “Relay for Life Japan” (Organizer: Japan Cancer Society etc.), a charity activity aiming to support cancer patients and their families, and encourage the entire community to confront and conquer cancer...

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies,...

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe.   ]The two...

First Fc Fusion Therapy Approved for haemophilia B in the EU to Provide Extended Protection Against Bleeds Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolix® (rFIXFc), their extended half-life...

Mylan N.V. announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...